Search Results
Your search for A matches 32916 pages
Showing 10251 - 10300Bristol Myers Squibb Foundation and National Medical Fellowships Launch Program to Increase Diversity in Clinical Trials
The Bristol Myers Squibb Foundation and National Medical Fellowships recently announced their new partnership, which is aimed at improving diversity in clinical trials. Leveraging $100 million of the previously announced commitment to diversity and inclusion from Bristol Myers Squibb and the...
What Is the Measure of Minimal Residual Disease in AML?
Relapse is the primary obstacle to cure in leukemia. The term minimal residual disease (MRD) was coined in the early 1990s to describe finding a disease-specific marker in the context of a morphologic-appearing remission. The technique first used for MRD detection was the Southern blot (!), but the ...
Meta-analysis Shows Superior Disease-Free and Overall Survival With Measurable Residual Disease Negativity in AML
In a systematic review and meta-analysis reported in JAMA Oncology, Nicholas J. Short, MD, of The University of Texas MD Anderson Cancer Center, and colleagues, found that measurable residual disease (MRD) negativity is associated with superior disease-free and overall survival in patients with...
Older Woman With Eye Tumor
The text and photograph here are excerpted from a four-volume series of books titled Oncology: Tumors & Treatment, A Photographic History, The Antiseptic Era 1876–1900 by Stanley B. Burns, MD, FACS, and Elizabeth A. Burns. The photograph appears courtesy of Stanley B. Burns, MD, and The Burns...
Facing Life’s Adversities, Even Cancer, From the Back of a Horse Named Buddy
“A bald eagle skims along the bluff where windblown Douglas firs, their exposed roots like talons, grip the eroding cliffs. Gulls circle and warn the bird of prey not to get too close. One hundred fifty feet below, the Salish Sea crashes and stretches west to the Pacific.” So begins Wild Ride Home: ...
Edward J. Benz, Jr, MD, Receives 2020 ASH Award for Leadership in Promoting Diversity
The 2020 American Society of Hematology (ASH) Award for Leadership in Promoting Diversity was awarded to Edward J. Benz, Jr, MD, President and Chief Executive Officer Emeritus of the Dana-Farber Cancer Institute and the Richard and Susan Smith Distinguished Professor at Harvard Medical School. Dr....
Addressing Disparities in Care Among Black Men and Women With Cancer
The American Cancer Society and Pfizer have approved grants totaling more than $3.7 million focused on reducing racial disparities in care and helping to optimize cancer outcomes for Black men and women in 10 communities. The goal is to address systemic race-related barriers and disparities in the...
The Lung Microbiome May Affect Lung Cancer Pathogenesis and Prognosis
Enrichment of the lungs with oral commensal microbes was associated with advanced-stage disease, worse prognosis, and tumor progression in patients with lung cancer, according to results from a study published in Cancer Discovery, a journal of the American Association for Cancer Research.1 “The...
Progress Report on Checkpoint Inhibitors in Rare Tumors
Immune checkpoint inhibitors may prove to be effective in treating patients with two rare cancer types—leptomeningeal metastases and angiosarcoma, according to early-phase clinical trials reported at the 2020 Annual Meeting of the Society for Immunotherapy of Cancer (SITC), which was held virtually ...
Dana-Farber/Brigham and Women’s Cancer Center and Stamford Hospital Expand Collaboration
Stamford Health and Dana-Farber/Brigham and Women’s Cancer Center (DF/BWCC) formally announced an exclusive, expanded collaboration to increase access to DF/BWCC experts and resources for patients at Stamford Health’s Carl & Dorothy Bennett Cancer Center. Stamford Health first joined the...
Immunotherapy for Triple-Negative Breast Cancer: An Evolving Story
Immunotherapy with checkpoint inhibitors, established as a treatment of many solid tumors, may be finding a role in the treatment of breast cancer. The current state of the art regarding immunotherapy for triple-negative breast cancer was the focus of a talk by Heather L. McArthur, MD, MPH, Medical ...
Emerging Data on PARP Inhibition in Prostate Cancer
Prostate cancer has lagged behind other solid tumors with regard to molecularly targeted therapy and precision medicine, with no targeted therapies approved specifically in prostate cancer, but that has changed with the recent approval in 2020 of a PARP (poly [ADP-ribose] polymerase) inhibitor for...
Understanding Breast Cancer Diagnosis and Treatment Disparities in Resource-Challenged Nations
Cancer is the second leading cause of death in the Caribbean. Adding to this growing burden, many of the nations in this geographically spread region have under-resourced health-care systems and a lack of cohesive approaches to the delivery of cancer care. To shed light on the public health...
Researchers Join $10 Million Project to Better Understand Sex Differences in Brain Cancer Outcomes
Researchers from Penn State College of Medicine are participating in a $10 million project to better understand why men and women with a common and deadly type of brain cancer have different survival rates. The investigators hope the study results can be used to develop new therapeutic approaches...
Physician-Scientist Judah Folkman, MD, Faced Years of Skepticism Before His Theory of Angiogenesis Was Proven
That Moses Judah Folkman would buck tradition, breaking his family’s long line of rabbinical succession and pursuing a career in science and medicine instead, was evident from the time he was a young child. Born in Cleveland on February 24, 1933, the first child of Rabbi Jerome and Bessie Folkman, ...
ASH Recognizes Admiral Brett Giroir, MD, With 2020 Outstanding Service Award
The American Society of Hematology (ASH) honored Admiral Brett Giroir, MD, Assistant Secretary for Health at the U.S. Department of Health and Human Services (HHS), for his outstanding support of hematology research and patient care. At the all-virtual annual meeting, Admiral Giroir received the...
Front-Line Nonchemotherapy Regimens May Improve Long-Term Outcomes in CLL
An assortment of agents has been approved in the United States for the first-line treatment of chronic lymphocytic leukemia (CLL), and all of them are effective, explained Richard Furman, MD, of Weill-Cornell Medical College, NewYork-Presbyterian Hospital, New York. In the modern era, most patients ...
Hannah Hazard-Jenkins, MD, Named Permanent Director of the WVU Cancer Institute
Hannah Hazard-Jenkins, MD, Associate Chair of Surgery for Cancer Services, has been named permanent Director of the West Virginia University (WVU) Cancer Institute after having served in the position on an interim basis since January. “As a native West Virginian, it is my honor to serve in this...
Expert Point of View: Joel W. Neal, MD, PhD
Invited discussant of the abstract, Joel W. Neal, MD, PhD, Associate Professor of Medicine at Stanford University, called this real-world analysis novel,1 given the decreasing number of patients treated with single-agent immunotherapy. “I think we’re unlikely to have a larger prospective study [in...
Lung Cancer Progression-Free Survival With Immunotherapy Varies Significantly by Tumor-Mutation Subtype, Real-World Data Show
A real-world study of single-agent immune checkpoint inhibitors in driver-mutated non–small cell lung cancer (NSCLC) has demonstrated significant variation in progression-free survival between mutation subtypes, according to data presented during the International Association for the Study of Lung...
Daniel D. Von Hoff, MD, FACP, FASCO, FAACR, Receives Inaugural AACR Scientific Achievement Award Established in His Honor
The American Association for Cancer Research (AACR) recently announced that Daniel D. Von Hoff, MD, FACP, FASCO, FAACR, will receive the inaugural AACR Daniel D. Von Hoff Award for Outstanding Contributions to Education and Training in Cancer Research. Dr. Von Hoff is being recognized for his...
Early-Stage Lung Cancer: An Overview of the Clinical Trial Landscape
Although early-stage, resectable disease represents the best chance for meaningful long-term survival and cure for patients with lung cancer, there are still high rates of recurrence. According to Rajwanth Veluswamy, MD, MSCR, neoadjuvant and adjuvant treatments are needed to improve surgical...
Expert Point of View: Ramesh Rengan, MD, PhD
Formal discussant of this trial, Ramesh Rengan, MD, PhD, Professor and Chair, Department of Radiation Oncology, University of Washington, and Professor, Fred Hutchinson Cancer Research Center, Seattle, commented: “My interpretation in the follow-up period is that low-dose radiation therapy is...
Low-Dose Radiotherapy for COVID-19–Related Pneumonia
Whole-lung low-dose radiation therapy led to quicker recovery from COVID-19–related pneumonia in hospitalized and oxygen-dependent patients compared with matched controls treated with best supportive care and physician’s choice of anti–COVID-19 therapy, according to the results of a small trial.1...
Expert Point of View: Thomas J. Dilling, MD, MS
Formal discussant Thomas J. Dilling, MD, MS, of Moffitt Cancer Center, Tampa, Florida, congratulated the authors on this study. He noted that early findings from both treatment arms showed similar rates of grade 3 and higher toxicity. “However, in the [four-fraction] arm, a fatal event occurred in...
Single-Fraction SBRT May Be Equivalent to Four in Patients With Oligometastatic Lung Disease
Delivering stereotactic body radiation therapy (SBRT also called stereotactic ablative radiotherapy) in one or four treatment sessions led to similar outcomes in patients with up to three lung metastases (ie, oligometastatic disease) in the phase II randomized SAFRON II trial. The study, conducted...
Expert Point of View: Matthijs Oudkerk, MD
Matthijs Oudkerk, MD, Professor of Radiology at the University Medical Center Groningen, Netherlands, and Principal Investigator for Radiology of the NELSON Lung Cancer Detection Study, stressed that detecting individuals who have early-stage lung cancer with more virulent biologic behavior is...
Surgical Resection of Stage I Lung Cancer: Rating the Evidence of Benefit
A recent report from the U.S. Preventive Services Task Force (USPSTF) has undermined the evidentiary basis for the primary treatment of stage I non–small cell lung cancer (NSCLC) while rating the evidence for the benefit of screening as “high.”1 According to David F. Yankelevitz, MD, these...
Geriatric Assessment: Vital Element in Individualizing Care for Older Patients With Cancer
Caring for older adults with cancer is the purview of every oncologist. Over the next 30 years, the older adult population (65 years and older) will represent the fastest-growing segment of the world population. Globally, the number of persons 80 years and older is expected to triple from 143...
FDA and AACR Launch Project Livin’ Label
The American Association for Cancer Research (AACR) and the U.S. Food and Drug Administration (FDA) will collaborate on Project Livin’ Label, a new educational initiative that aims to foster broad understanding of specific oncology product labels and increase awareness of recent oncology drug FDA...
Living Well Before We Die
Editor’s Note: The following essay was first published in 2011. It is being reprinted here with permission from the author and publisher. In 2020, the American Academy of Hospice and Palliative Medicine (AAHPM) now includes more than 5,000 members; the annual meeting convenes more than 3,200...
Erratum
In the November 10, 2020, issue of The ASCO Post, the article “Cancer on the Global Stage: Incidence and Cancer-Related Mortality in Chile” contained errors with regard to the head shots of the coauthors. A photo of Augusto León G-H, MD (the son of another coauthor with a similar name), was...
Cancer on the Global Stage: Incidence and Cancer-Related Mortality in Colombia
Colombia is located in the northwestern corner of South America, geographically privileged with coasts on both the Atlantic and Pacific Oceans, the Andean region, and the Amazon rainforest. Based on its population of nearly 50 million (see Table 1), Colombia is the second largest country in South...
Discerning the Underlying Mechanisms of Endometrial Cancer Disparities in Black Women
Endometrial cancer is the fourth most common cancer diagnosed in the United States, and the seventh most common cause of cancer death among women.1 This year, nearly 66,000 women will be diagnosed with the cancer, and about 12,600 will die of the disease.2 And although endometrial cancer is one of...
An Early Love of the Duck-Billed Platypus Sparks a Career in Cancer Research
Elaine R. Mardis, PhD, Co-Director of the Institute for Genomic Medicine at Nationwide Children’s Hospital, was born and reared in North Platte, a small city located in the west-central part of Nebraska. “My love of science was sparked and nurtured by my father, who was a chemistry professor for...
SABCS 2020: Patients With Breast Cancer Undergoing Radiotherapy May Have Underrecognized Side Effects
Among patients with breast cancer treated with radiotherapy, symptoms were commonly underrecognized in reports of pain, pruritus, edema, and fatigue, with younger patients and Black patients having significantly increased odds of symptom underrecognition. These findings were reported by Reshma...
Breaking the Cultural Norms: A Young Indian Girl Attains Her Dream of Becoming a Global Oncologist
For this installment of the Living a Full Life series, guest editor Jame Abraham, MD, spoke with Bhawna Sirohi, FRCP, who is currently the lead medical oncologist at the Apollo Proton Cancer Centre in Chennai, Tamil Nadu, India. Along with her work in the clinic and her research endeavors, Dr....
CU Cancer Center Leukemia Researcher Receives NCI Outstanding Investigator Award
Craig Jordan, PhD, University of Colorado (CU) Cancer Center member and Chief of the Hematology Division in the CU School of Medicine, was awarded a 2020 National Cancer Institute (NCI) Outstanding Investigator Award. This 7-year grant supports investigators with outstanding records of...
SABCS 2020: Opioid and Sedative-Hypnotic Use After Mastectomy With Reconstructive Surgery
Women who undergo mastectomy with reconstructive surgery as part of breast cancer treatment may face the risk of persistent use of opioids and sedative-hypnotic drugs, according to data presented by Jacob Cogan, MD, and colleagues at the 2020 San Antonio Breast Cancer Symposium (Abstract GS3-08)....
SABCS 2020: Meta-analysis of Pregnancy Outcomes in Breast Cancer Survivors
A large meta-analysis of breast cancer survivors of childbearing age indicated that they are less likely than the general public to become pregnant and may face a higher risk of certain complications, such as preterm labor. However, most survivors who do become pregnant deliver healthy babies and...
Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Neoplasms
The ASCO Post is pleased to present the Hematology Expert Review, an ongoing feature that quizzes readers on issues in hematology. In this installment, Drs. Abutalib and Medeiros explore extranodal marginal zone lymphoma of mucosa-associated lymphoid neoplasms (MALT lymphomas). For each quiz...
SABCS 2020: Radiotherapy Omission After Breast-Conserving Surgery for Older Patients With HR-Positive Breast Cancer
Patients aged 65 or older with hormone receptor (HR)-positive breast cancer who did not receive radiation therapy after breast-conserving surgery had higher rates of local recurrence but similar 10-year survival rates when compared to patients who received postoperative radiation therapy, according ...
How Did the COVID-19 Pandemic Affect Initiation of Cancer Treatment in England?
In a retrospective analysis reported in The Lancet Oncology, Clark et al found that new prescriptions for systemic anticancer treatment in England initially declined significantly after societal lockdown in response to the COVID-19 pandemic. However, they then increased to higher than prepandemic...
Interference of Clonal Hematopoiesis in DNA Repair Genes With Prostate Cancer Plasma Cell-Free DNA Testing
In a study reported in JAMA Oncology, Jensen and colleagues found that clonal hematopoiesis of indeterminate potential (CHIP) involving DNA repair genes can interfere with prostate cancer plasma cell-free DNA testing used to determine eligibility for poly (ADP-ribose) polymerase (PARP) inhibitor...
Assessing the Progress Made in Global Cancer Care and Looking Toward the Future
In October 2020, Her Royal Highness Princess Dina Mired of Jordan ended her 2-year tenure as President of the Union for International Cancer Control (UICC), a global organization with more than 1,198 members from 172 countries and territories committed to reducing the cancer burden and...
ASCO Issues Comprehensive Recommendations to Strengthen Cancer Care and Research During and Beyond the COVID-19 Pandemic
On December 8, ASCO issued comprehensive recommendations to guide the cancer community’s eventual recovery from the COVID-19 pandemic. By applying lessons learned during the pandemic, ASCO’s Road to Recovery Report: Learning From the COVID-19 Experience to Improve Clinical Research and Cancer Care...
Caron A. Jacobson, MD, on Treating Large B-Cell Lymphoma With Axicabtagene Ciloleucel
Caron A. Jacobson, MD, of the Dana-Farber Cancer Institute, discusses results from the ZUMA-9 C2 study, an ongoing trial that is exploring axicabtagene ciloleucel in patients with relapsed or refractory large B-cell lymphoma (Abstract 2100).
Matthew S. Davids, MD, on CLL/SLL: New Data on Ibrutinib, Venetoclax, and Rituximab Therapies
Matthew S. Davids, MD, of Dana-Farber Cancer Institute, summarizes three key studies from a session he co-moderated on ibrutinib plus venetoclax for first-line treatment of patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL), long-term responses to these agents for ...
ASH 2020: Early Signs of Risk for Myeloproliferative Neoplasms May Appear in Childhood or in Utero
Genetic mutations linked to myeloproliferative neoplasms may emerge in childhood or even in utero, decades before they cause cancer, according to a late-breaking abstract presented today at the 2020 American Society of Hematology (ASH) Annual Meeting & Exposition by Jyoti Nangalia, MBBChir, and ...
Proportion of Never-Smokers Among Patients With Lung Cancer in Seven U.S. States
In a study reported in a research letter in JAMA Oncology, Siegel et al found that never-smokers accounted for 12.5% of patients diagnosed with lung cancer in seven U.S. states during a recent 6-year period, with women accounting for a higher proportion than men. Study Details The study included...
